Stratedigm S100EON high-parameter flow cytometer to support multi-institutional research programs

标题：Xandigm S100 EON高参数流式细胞仪支持多机构 研究项目 翻译后摘要：免疫建模，分析和诊断共享资源（IMAD）是一个CLIA- 经过认证的核心设施，可对各种大型多功能流式细胞仪进行高度验证， 机构NIH资助的研究项目。它是指定的免疫学核心设施， 加州癌症联盟、加州大学戴维斯分校阿尔法诊所和加州大学戴维斯分校综合医院 癌症中心加州癌症联盟是一个由国家癌症研究所资助的联盟，其中包括 来自希望之城、南加州大学、加州大学的调查人员 戴维斯和斯坦福大学。加州大学戴维斯分校阿尔法诊所运行本地和多机构CIRM， NIH申办的临床研究。它的合作伙伴包括加州圣地亚哥大学， 加州圣弗朗西斯科大学和纪念斯隆凯特琳癌症中心。目标 目前NIH S10应用的主要目的是支持购买iodigm S100 EON， 是高参数流式细胞仪。该仪器极低的运行成本及其 完全自动化流式细胞术工作流程（即染色，离心，孵育， 装载等）使这种仪器特别适合于IMAD，并将其与其他仪器分开， 目前可用的其它流式细胞仪。这些独特的功能将大大降低每 样品采集成本，并增加可使用IMAD处理的样品数量 现有资源。降低每个样品的成本和增加吞吐量都是有利的。 如果IMAD要满足他们目前的需求，这是必不可少的，这是显而易见的，他们的大量积压， 冷冻标本就目前而言，IMAD可能是该大学唯一的免疫学核心 加州系统的流式细胞仪。而且即使IMAD的调查人员 愿意出差，萨克拉门托没有高参数流量分析仪可供他们使用 使用.流式细胞仪的缺乏是阻碍IMAD 为用户提供卓越的价格和周转时间。IMAD的重点是 为全球各地的研究人员提供高通量、高度验证的基于流动的分析， 国家最后，IMAD经过高度验证的样品制备和采集服务 与目前的UC Davis核心设施重叠。

Title: Stratedigm S100EON high-parameter flow cytometer to support multi-institutional research programs Abstract: The Immune Modeling, Analysis, and Diagnostic Shared Resource (IMAD) is a CLIA- certified core facility that performs highly validated flow cytometry for various large multi- institutional NIH-funded research programs. It is the designated immunology core facility for the California Cancer Consortium, the UC Davis Alpha Clinic, and the UC Davis Comprehensive Cancer Center. The California Cancer Consortium is an NCI-funded consortium which includes investigators from the City of Hope, University of Southern California, University of California Davis, and Stanford. The UC Davis Alpha clinic runs local and multi-institutional CIRM and NIH-sponsored clinical studies. Its partners include the University of California San Diego, University of California San Francisco, and the Memorial Sloan Kettering Cancer Center. The goal of the current NIH S10 application is to support the purchase of the Stratedigm S100EON, which is a high-parameter flow cytometer. The extremely low operating cost of this instrument and its ability to fully automate the flow cytometry work flow (i.e. staining, centrifugation, incubation, loading, etc.) make this instrument especially suited for the IMAD and separate it from other the other flow cytometers currently available. These unique features will dramatically lower the per sample acquisition cost and increase the number of samples that can processed with IMAD's existing resources. Both lowering the per sample cost and increasing the throughput capacity are essential, if the IMAD is to meet their current demand, which is evident by their large backlog of frozen specimens. As it stands, the IMAD is possibly the only immunology core in the University of California system without a dedicated flow cytometer. Also, even if the IMAD investigators are willing to travel, there are no high-parameter flow analyzers available in Sacramento for them to use. The absence of a flow cytometer is the major bottleneck that prevents the IMAD from providing exceptional pricing and turnaround time for its users. The IMAD is focused on providing high throughput, highly validated flow-based assays to investigators across the country. Finally, IMAD highly validated sample preparation and acquisition services do not overlap with current UC Davis core facilities.